Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
Treatment of acute myeloid leukemia (AML) has improved in recent years and several new therapeutic options have been approved. Most of them include mutation-specific approaches (e.g., gilteritinib for AML patients with activating <i>FLT3</i> mutations), or are restricted to such defined...
Guardado en:
Autores principales: | Maximilian Fleischmann, Ulf Schnetzke, Andreas Hochhaus, Sebastian Scholl |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
MDPI AG
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/92d98bbe561a495e8ea86d12d1f69b9f |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Maximilian Fleischmann, et al.
Publicado: (2021) -
Profile of sapacitabine: potential for the treatment of newly diagnosed acute myeloid leukemia in elderly patients
por: Lim MY, et al.
Publicado: (2014) -
Conventional Cytogenetic and Molecular Analysis in Acute Myeloid Leukemia (AML) and Their Association with Overall Survival
por: Shakeri S., et al.
Publicado: (2021) -
Outcome After Azacitidine Treatment in Patients with High-Risk Myeolodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia – A Single Center Experience (Preliminary Data)
por: Varbanova V., et al.
Publicado: (2020) -
Targeted treatment of acute myeloid leukemia in older adults: role of gemtuzumab ozogamicin
por: Hien K Duong, et al.
Publicado: (2009)